Page last updated: 2024-08-01 21:34:27

3,8-dibromo-7-hydroxy-4-methylchromen-2-one

Description

3,8-dibromo-7-hydroxy-4-methylchromen-2-one: structure in first source [MeSH]

3,8-dibromo-7-hydroxy-4-methyl-1-benzopyran-2-one : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID5795340
CHEMBL ID273101
CHEBI ID109100
MeSH IDM0521394

Synonyms (18)

Synonym
EU-0031872
3,8-dibromo-7-hydroxy-4-methyl-2h-chromen-2-one
MLS000673770
smr000315011
CHEBI:109100
2QC6
DB07802
AKOS002126114
CHEMBL273101 ,
3,8-dibromo-7-hydroxy-4-methylchromen-2-one
HMS2740A24
HMS3604I18
SR-01000103263-1
sr-01000103263
bdbm50508989
FT-0724993
Q27097013
PD005020

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.0119AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.5893AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency35.4813AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency23.9341AID588342
acid sphingomyelinaseHomo sapiens (human)Potency25.1189AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.1189AID588456
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.1838AID1030
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency39.8107AID1466; AID2242
huntingtin isoform 2Homo sapiens (human)Potency25.1189AID1688
importin subunit beta-1 isoform 1Homo sapiens (human)Potency39.3106AID540253; AID540263
snurportin-1Homo sapiens (human)Potency39.3106AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency22.3872AID540253
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.1251AID588590
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.6228AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.1838AID504327
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.8107AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.8107AID1466

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, Casein kinase II subunit alphaZea maysIC500.1000AID977608
Casein kinase II subunit alphaHomo sapiens (human)Ki0.0600AID1539764

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
ISSN: 0022-2623
Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
ISSN: 1552-454X
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2022Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1
ISSN: 1475-6374
AID317243Inhibition of CK2 in rat liver2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
ISSN: 0022-2623
Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.
AID1539764Inhibition of CK2alpha (unknown origin)2019European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254Small molecule modulators targeting protein kinase CK1 and CK2.

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
3-hydroxy-1-benzopyran-2-onehydroxycoumarin00low000000
isoscopoletinaromatic ether;
hydroxycoumarin
plant metabolite00low000000
fraxinaromatic ether;
beta-D-glucoside;
hydroxycoumarin
anti-inflammatory agent;
hepatoprotective agent;
plant metabolite
00low000000
fraxetinaromatic ether;
hydroxycoumarin
anti-inflammatory agent;
antibacterial agent;
antimicrobial agent;
antioxidant;
apoptosis inducer;
apoptosis inhibitor;
Arabidopsis thaliana metabolite;
hepatoprotective agent;
hypoglycemic agent
00low000000
scopoletinhydroxycoumarinplant growth regulator;
plant metabolite
00low000000
hymecromonehydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
00low000000
daphnetinhydroxycoumarin00low000000
daphnoretinaromatic ether;
hydroxycoumarin
antineoplastic agent;
antiviral agent;
metabolite
00low000000
esculetinhydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter
00low000000
esculinbeta-D-glucoside;
hydroxycoumarin
antioxidant;
metabolite
00low000000
7-hydroxycoumarinhydroxycoumarinfluorescent probe;
food component;
plant metabolite
00low000000
7-hydroxy-8-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-4-methyl-1-benzopyran-2-onehydroxycoumarin00low000000
7-demethylsuberosinhydroxycoumarinplant metabolite00low000000
isofraxidinhydroxycoumarin00low000000
4-methylesculetinhydroxycoumarinanti-inflammatory agent;
antioxidant;
hyaluronan synthesis inhibitor
00low000000
osthenolhydroxycoumarinantifungal agent;
plant metabolite
00low000000
5,7-dihydroxy-4-methylcoumarinhydroxycoumarin00low000000
7,8-dihydroxy-4-methylcoumarinhydroxycoumarin00low000000
7-hydroxy-3-(4-methoxyphenyl)-4-methylcoumarinhydroxycoumarin;
monomethoxybenzene
00low000000
2-(5,7-dihydroxy-4-methyl-2-oxo-1-benzopyran-3-yl)acetic acid ethyl esterhydroxycoumarin00low000000
6-ethyl-7-hydroxy-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-1-benzopyran-2-onehydroxycoumarin00low000000
3-bromo-7-hydroxy-4,8-dimethyl-1-benzopyran-2-onehydroxycoumarin00low000000
5,7-dihydroxy-4-methyl-3-(phenylmethyl)-1-benzopyran-2-onehydroxycoumarin00low000000
urolithin dhydroxycoumarin00low000000
7-hydroxy-8-methyl-4-[[methyl-(phenylmethyl)amino]methyl]-1-benzopyran-2-onehydroxycoumarin00low000000
3-(dimethylamino)benzoic acid (7-hydroxy-2-oxo-1-benzopyran-4-yl)methyl esterhydroxycoumarin00low000000
6-chloro-7-hydroxy-4-(4-morpholinylmethyl)-1-benzopyran-2-onehydroxycoumarin00low000000
6-chloro-4-[[(2-fluorophenyl)methyl-methylamino]methyl]-7-hydroxy-1-benzopyran-2-onehydroxycoumarin00low000000
6-chloro-3-[2-[4-[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]-1-piperazinyl]-2-oxoethyl]-7-hydroxy-4-methyl-1-benzopyran-2-onehydroxycoumarin00low000000
novobiocincarbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols
antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
00low000000
dicumarolhydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
00low000000
acenocoumarolC-nitro compound;
hydroxycoumarin;
methyl ketone
anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
00low000000
warfarinbenzenes;
hydroxycoumarin;
methyl ketone
00low000000
coumatetralylhydroxycoumarin00low000000
4,7-Dihydroxy-2H-1-benzopyran-2-onehydroxycoumarin00low000000
7-(diethylamino)-4-hydroxy-1-benzopyran-2-onehydroxycoumarin00low000000
phenprocoumonhydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
00low000000
4'-hydroxywarfarinhydroxycoumarin00low000000
7-hydroxywarfarinhydroxycoumarin00low000000
coumachlorhydroxycoumarin00low000000
4-hydroxycoumarinhydroxycoumarin00low000000
ethyl biscoumacetatehydroxycoumarin00low000000
4-hydroxy-3-(1-piperidinylmethyl)-1-benzopyran-2-onehydroxycoumarin00low000000
10-hydroxywarfarinhydroxycoumarin00low000000
pacific blue succinimidyl esterhydroxycoumarin;
N-hydroxysuccinimide ester;
organofluorine compound
fluorochrome00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
4,5,6,7-tetrabromo-2-azabenzimidazole201920195.0low000010
emodintrihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
201920195.0low000010
1,2,5,8-tetrahydroxy anthraquinonetetrahydroxyanthraquinoneEC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor201920195.0low000010
cki 7isoquinolines;
organochlorine compound;
primary amino compound;
sulfonamide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor201920195.0low000010
4,5,6,7-tetrabromobenzimidazole201920195.0low000010
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
201920195.0low000010
apigenintrihydroxyflavoneantineoplastic agent;
metabolite
201920195.0low000010
hymecromonehydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
2008200816.0low000100
7-hydroxycoumarinhydroxycoumarinfluorescent probe;
food component;
plant metabolite
2008200816.0low000100
fisetin3'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone
anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
201920195.0low000010
coumestrolcoumestans;
delta-lactone;
polyphenol
anti-inflammatory agent;
antioxidant;
plant metabolite
201920195.0low000010
ellagic acidcatechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol
antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
2008201910.5low000110
casein kinase ii201920195.0low000010
5,7-dihydroxy-4-methylcoumarinhydroxycoumarin2008200816.0low000100
d 4476imidazoles201920195.0low000010
4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamineaminopyrimidine;
imidazoles;
monofluorobenzenes
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor201920195.0medium000010
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid2008201910.5high000110
cx 4945201920195.0low000010
cx 5011201920195.0high000010
pf 4800567aromatic ether;
monochlorobenzenes;
oxanes;
pyrazolopyrimidine
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor201920195.0medium000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
emodintrihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
2010201014.0low000100
7-hydroxycoumarinhydroxycoumarinfluorescent probe;
food component;
plant metabolite
2010201014.0low000100
casein kinase ii2008201015.0low000200
warfarinbenzenes;
hydroxycoumarin;
methyl ketone
2008200816.0low000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Inflammation02010201014.0high000100
Innate Inflammatory Response02010201014.0high000100
Malaria, Falciparum02014201410.0high000010
Plasmodium falciparum Malaria02014201410.0high000010